Inari Medical, Inc. NARI
We take great care to ensure that the data presented and summarized in this overview for Inari Medical, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NARI
View all-
Black Rock Inc. New York, NY8.48MShares$430 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.6MShares$284 Million0.01% of portfolio
-
Hcc Manager LLC Chicago, IL2.91MShares$148 Million80.17% of portfolio
-
Franklin Resources Inc San Mateo, CA2.57MShares$130 Million0.04% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.31MShares$117 Million0.05% of portfolio
-
Alliancebernstein L.P. New York, NY2.21MShares$112 Million0.04% of portfolio
-
State Street Corp Boston, MA2.06MShares$105 Million0.0% of portfolio
-
Brown Advisory Inc1.82MShares$92.4 Million0.12% of portfolio
-
Morgan Stanley New York, NY1.57MShares$79.8 Million0.01% of portfolio
-
Credit Suisse Ag Zurich, V81.29MShares$65.2 Million0.06% of portfolio
Latest Institutional Activity in NARI
Top Purchases
Top Sells
About NARI
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Insider Transactions at NARI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 28
2024
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
60,000
-6.48%
|
$3,000,000
$50.13 P/Share
|
|
May 28
2024
|
Andrew Hykes President and CEO |
SELL
Open market or private sale
|
Direct |
3,000
-0.64%
|
$150,000
$50.0 P/Share
|
|
May 20
2024
|
Rebecca Chambers Director |
SELL
Open market or private sale
|
Direct |
964
-8.84%
|
$43,380
$45.39 P/Share
|
|
May 16
2024
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
40,000
-2.09%
|
$1,840,000
$46.75 P/Share
|
|
May 13
2024
|
Hill, Mitch C. Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,000
-1.08%
|
$270,000
$45.59 P/Share
|
|
May 13
2024
|
Hill, Mitch C. Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+3.1%
|
$0
$0.46 P/Share
|
|
May 01
2024
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
38,549
-1.28%
|
$1,619,058
$42.76 P/Share
|
|
Apr 24
2024
|
Catherine M. Szyman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+15.54%
|
$173,292
$42.41 P/Share
|
|
Apr 24
2024
|
Robert Keith Warner Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+25.35%
|
$173,292
$42.41 P/Share
|
|
Apr 24
2024
|
Donald B Milder Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+1.57%
|
$173,292
$42.41 P/Share
|
|
Apr 24
2024
|
Jonathan D Root Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+0.76%
|
$173,292
$42.41 P/Share
|
|
Apr 24
2024
|
Cynthia L Lucchese Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+9.7%
|
$173,292
$42.41 P/Share
|
|
Apr 24
2024
|
Dana G Mead Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+27.01%
|
$173,292
$42.41 P/Share
|
|
Apr 24
2024
|
William Hoffman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+0.41%
|
$173,292
$42.41 P/Share
|
|
Apr 24
2024
|
Rebecca Chambers Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,126
+27.44%
|
$173,292
$42.41 P/Share
|
|
Apr 16
2024
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
1,451
-0.14%
|
$58,040
$40.0 P/Share
|
|
Apr 12
2024
|
Hill, Mitch C. Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,000
-3.2%
|
$240,000
$40.96 P/Share
|
|
Apr 12
2024
|
Hill, Mitch C. Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+3.1%
|
$0
$0.46 P/Share
|
|
Apr 01
2024
|
Hill, Mitch C. Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,067
-0.28%
|
-
|
|
Apr 01
2024
|
Andrew Hykes President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,222
-0.22%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 103K shares |
|---|---|
| Exercise of conversion of derivative security | 167K shares |
| Open market or private purchase | 56.1K shares |
| Payment of exercise price or tax liability | 34K shares |
|---|---|
| Open market or private sale | 547K shares |
| Bona fide gift | 200K shares |